Drug-Excipients Compatibility Studies of Molnupiravir in an Attempt of Developing a Stable Molnupiravir Capsule Formulation for the Treatment of COVID-19

ABSTRACT

Background: Molnupiravir is an antiviral medication primarily used for the treatment of COVID-19. Clinical trials have shown that molnupiravir reduces the risk of hospitalization and death due to COVID- 19 when taken early in the course of infection. The USFDA had granted an EUA (emergency use authorization) in December 2021 for molnupiravir to treat COVID-19. Many other countries have also authorized its use under emergency provisions. The current research focuses on performing Drug-Excipients Compatibility Studies of Molnupiravir in an attempt of developing a Stable Molnupiravir Capsule formulation-200 mg. Materials and Methods: Compatibility of various excipients with Molnupiravir API was studied. Drug and individual excipients were mixed in 1:1 ratio and filled in USP Type I transparent glass vials. Samples were tested at initial, 15 days, 30 days for Description, Assay and Related substances. Appropriate excipients were chosen based on the results obtained. With the selected excipients 3 different capsule formulations were prepared by varying the excipients quantities and were studied for Assay, Related Substances and Dissolution profile for determining the best suitable formula. Results: Among three different formulations manufactured, The Assay, Related Substances and Dissolution profile of Formulation 3 was found satisfactory. Conclusion: Formulation 3 was found to be the best suitable formula and was considered for formulating Molnupiravir 200 mg Capsules and for further studies.

KEYWORDS

• Antiviral
• COVID-19
• Drug-Excipients Compatibility Studies
• Emergency Use
• Authorization
• Molnupiravir

Showing references and in-text citations exactly as published.

• DOI10.5530/ijper.20262891Copy

RELATED ARTICLES

Matched on section and article type within this issue of IJPER.

• Article · VOLUME 60, ISSUE 3SDevelopment and evaluation of Dry Powder Inhalation Formulation of Remdesivir Nanosuspension by Spray Drying TechniqueArshad Shaikh, Mukesh Pandurang Ratnaparkhi, Sayali Vilas Jadhav, Shailendra Salvankar · pp. s1–s9Original ArticleSame type: Article
• Article · VOLUME 60, ISSUE 3SOptimized Green Synthesis Approaches of Phenytoin Using Divalent Sulfate Salts and Chromatographic Purity Assessment via A Novel RP-HPLC MethodArka Chakraborty, Rajarshi Nath, Biplab Debnath, Arijit Das, Anindya Bose, Shambo Panda · pp. s1–s8Original ArticleSame type: Article
• Article · VOLUME 60, ISSUE 3SFormulation and Evaluation of Beclomethasone Dipropionate Loaded Niosomal Gel for Topical UseMahesh Birajdar, Rohit Sarda, Shradha Tiwari, Dnyaneshwari Jadhav, Sameep Sonvane, Prakash Shivnechari, Kranti Satpute · pp. s918–s928Original ArticleSame type: Article
• Article · VOLUME 60, ISSUE 3SDesign and Development of Self-Micro Emulsifying Drug Delivery Systems of Rifaximin Using 32 Factorial DesignOnkar Vilas Jadhav, Twarita Dilip Deshpande, Udaykumar Baburao Bolmal, Anuj Jagannath Shinde, Shital Vishwas Patil · pp. s929–s943Original ArticleSame type: Article